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Abstract
The diagnostic work up of dementia may benefit from struc-
tured reporting of CT and/or MRI and the use of standardised
visual rating scales. We advocate a more widespread use of
standardised scales as part of the workflow in clinical and
research evaluation of dementia. We propose routine clinical
use of rating scales for medial temporal atrophy (MTA), glob-
al cortical atrophy (GCA) and white matter hyperintensities
(WMH). These scales can be used for evaluation of both CT
and MRI and are efficient in routine imaging assessment in
dementia, and may improve the accuracy of diagnosis. Our
review provides detailed imaging examples of rating
increments in each of these scales and a separate teaching file.
The radiologist should relate visual ratings to the clinical as-
sessment and other biomarkers to assist the clinician in the
diagnostic decision.
Teaching points
• Clinical dementia diagnostics would benefit from structured
radiological reporting.
• Standardised rating scales should be used in dementia
assessment.
• It is important to relate imaging findings to the clinically
suspected diagnosis.
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Introduction
The prevalence of dementia is increasing due to longer life
expectancy, including a large increase of populations aged 80-
years and older. A thorough investigation of suspected demen-
tia and pre-dementia stages is of high importance for early
diagnosis, caretaking and, if possible, treatment. Brain imag-
ing is included among the basic investigations in the work-up
of dementia in many countries. Knowledge on dementia and
particularly Alzheimer’s disease has increased significantly in
recent years, especially with regard to imaging methods and
their impact on differential diagnosis. Nevertheless, this
knowledge has not been fully implemented in clinical radio-
logical routine work, most likely due to lack of communica-
tion between academia and clinical practice. In this paper,we
describe how changes characteristic of common dementia dis-
orders can be assessed in a structured way using computed
tomography (CT) and magnetic resonance imaging (MRI).
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Established visual rating scores offer a practical, fast and in-
expensive means of improving the diagnostic accuracy
[1].Our review is based on a collaboration between
Karolinska Institutet, Uppsala University, Lund University,
Gothenburg University and other university hospitals in
Sweden, Norway and internationally as part of the imaging
Fig. 1 A. Widening of the ventricles on MRI. Interpretation key.
Numbers equal the corresponding image in the supplementary PDF file.
Appropriate wording for widening of the ventricles is: no, mild, moderate
or severe widening. a/1) There are no visual rating scales for the size of
the ventricles. Compare to the widening of a 25-year-old healthy
individual. b/2) A third ventricle with a diameter of >10 mm is
pathological at any age. c/6) No widening. d/16) No widening. e/17) In
between nowidening andmild widening. The third ventricle is wider than
usual. f/20)Mild widening. Note the slightly wide frontal horn on the left
side due to the frontal infarction. g/7)Mild widening h/9)Mild widening.
i/15) Approaching mild widening. j/12) Mild bifrontal widening and no
widening of posterior horns. k/11) Mild bifrontal widening and a left
posterior horn with moderate widening. l/3) In this case: mild, with a
moderate widening of the posterior horns. m/5) Mild widening of the
frontal horns and moderate of posterior horns. n/8)Mild widening, with
a moderate widening of frontal horns. o/19) In between mild and
moderate widening but closer to moderate. p/13) Mild central
widening, with the right posterior horn a bit wider, but not yet
moderate. q/10) Mild widening of frontal horns and moderate of the
posterior horns, especially the left posterior horn. r/14) Moderate
widening, especially of posterior horns. s/18) Severe dilatation of third
ventricle and moderate widening of the posterior horns. t/4) Severe
widening of the ventricles, especially of the frontal horns. B. Widening
of the ventricles on CT. Interpretation key. Numbers equal the
corresponding image in the supplementary PDF file. a/1) No widening.
The normative key. b/7)No widening, right deep MCA infarction is seen
in the image. c/3)No widening d/19) No widening but wide cavum septi
pellucidi et vergae. e/11)Nearly no widening. f/14)Between no widening
and mild. g/6) Normal to mild widening. h/9)Mild widening. i/12)Mild
widening. j/13)Mild widening. k/18) Mild widening of ventricles. l/17)
Mild widening of lateral ventricles. Cavum septi pellucidi et verge makes
ventricles look wider.m/15)Mild widening of the posterior horns without
exceeding into moderate widening. n/20)Mild widening of frontal horns
and a mild to moderate widening of the posterior horns. o/10) Mild
widening with a moderate widening of the left posterior horn. p/8) Mild
widening with a moderate widening of the right posterior horn. q/16)
Mild widening of frontal horns and moderate widening of posterior
horns. r/4) Mild to moderate widening s/5) A pronounced widening of
the third ventricle. Maybe this indicates atrophy of the basal ganglia and
thalami. t/2)Moderate widening
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cognitive impairment network (ICINET). ICINETwas formed
initially to standardise imaging dementia assessment, and rec-
ommend its use in clinical practice [2].
In normal ageing, cognitive functions may be reduced to
varying degree, with pronounced reduction in some cognitive
domains usually due to disease processeses leading to disabili-
ty. Criteria for dementia are met if the disability becomes
severe, affecting cognitive domains [3]. One of the most com-
mon causes of dementia is Alzheimer’s disease (60-70 %).
Hallmarks of the neurodegenerative process are abnormal pro-
duction and/or reduced clearance of the beta amyloid (Aβ)
protein which in its abnormal form is aggregated in so-called
plaques [4, 5]. Phosphorylation of tau protein leading to deg-
radation and destruction of cellular support structures is
another important sign [6]. These changes in combination
with other factors are most probably causing the extensive cell
destruction that develops during the course of the disease that
in its turn leads to cerebral atrophy of the brain, usually
starting in the medial temporal lobes [7–10]. Vascular
dementia is another cause of cognitive impairment, considered
to be the second most common form of dementia after
Alzheimer’s disease and is observed in about 30 % of all
dementia patients. Recently, an overlap between Alzheimer’s
disease and vascular dementia with small vessel disease has
been reported as a possible contributor and cause of dementia
[11–13]. Cerebral amyloid angiopathy and hypertensive
arteriopathy constitute the two most common small vessel
diseases and are thought to be important parts of the dementia
disease process [11, 12]. Other neurodegenerative diseases
with cognitive impairment are frontotemporal dementia (2 %
of all dementias [14]) and Lewy body dementia (4.2 % of all
diagnosed dementias [15]). Cognitive impairment may also
occur in, for example, depression and as a result of a brain
tumour, cerebral haemorrhage and stroke.
The diagnosis of dementia is based on clinical symptoms as
well as evidence of amyloid and tau pathology in the case of
Alzheimer’s disease [16]. MRI of the brain significantly in-
creases the confidence of a dementia diagnosis. Traditionally,
Fig. 1 (continued)
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CT and MRI were used to rule out disease that may lead to
cognitive impairment, such as for instance intracranial tumour
and multiple sclerosis. However, in the modern clinical work-
up of dementia, CT and MRI are cornerstones due to their
ability to detect patterns of atrophy that may be specific for a
neurodegenerative disease, for example medial temporal lobe
atrophy constitutes an early sign of Alzheimer’s disease [17,
18]. In addition, imaging substrates of cerebrovascular disease
are visualized and often the diagnosis of small vessel disease is
added after CT and MRI. The European leukoariosis and
disability (LADIS) studies have shown evidence that white
matter hyperintensities increase the risk of cognitive
decline (11).
In order to maximize the yield of brain imaging in
the clinical work-up of patients with cognitive impair-
ment, it is important that imaging findings are reported
consistently and according to established, validated rat-
ing scales [1, 19]. Here, we present a comprehensive
overview of the most important findings on routine CT
and MRI in dementia including visual scoring according
to established rating scales. It should be emphasized
that the assessment also can be performed on CT, which
is still the most widely used modalility in routine de-
mentia investigations. We suggest that these methods
are incorporated into clinical protocols and are used
for routine clinical image interpretation. Training to
use the scales and available reference images is impor-
tant for consistent accurate results of the visual evalua-
tion [19]. Therefore we also provide image examples
using the different rating scales (Figs. 1, 2, 3 and 4)
and separate teaching material.
MRI protocol
Three basic MRI-sequences should preferebely used for
the visual assessment : a T1-weighted 3D sequence to
assess structural changes, a T2-weighted fluid attenuated
inversion recovery (FLAIR) and a T2-weighted turbo
spin echo sequence to detect other pathological changes,
primarily white matter changes. We also propose the
addition of a sequence for assessing microbleeds that
could aid in the diagnosis of small vessel disease, pref-
erably the susceptibility weighted imaging (SWI)
sequence.
Structured assessment of CT and MRI
A structured radiological report with description of the
imaging findings is required to provide optimal informa-
tion to the referring clinician. The width of the sulci
and the ventricles, the degree of medial temporal lobe
atrophy, white matter changes and the occurrence of
infarctions, mass effect or other changes, leading to sec-
ondary dementia, must be included. Comparison with
previous radiological examinations is very important
since relatively rapid progression of atrophy supports
the suspicion of neurodegenerative dementia.
A radiological report should describe:
•Medial temporal lobe atrophy (MTA) (Scheltens score with explanation)
• General or local widening of sulci (Global Cortical Atrophy (GCA)
stage with explanation)
• Width of ventricles
•White matter hyperintensities (WMH) (score according to Fazekas scale
with explanation)
• Size and position of infarcts
• Other changes (tumour, normal pressure hydrocephalus, subdural
hematoma etc.)
• Comparison with previous examinations (progression of atrophy or
white matter changes etc.)
• CONCLUSION: assessment of findings in relationship to clinical
suspicion and other examinations such as CSF, PET or SPECT.
Medial temporal lobe atrophy (MTA) – Scheltens scale
A rating scale for visual assessment of medial temporal atro-
phy (MTA) was developed by Philip Scheltens’ research
group in Amsterdam in 1992 [20, 21]. This scale has been
used in a large number of studies and is also included in the
research criteria for the diagnosis of Alzheimer’s disease [22].
The height of the hippocampus, as well as the width of the
temporal horns and choroid fissure are assessed on standard-
ized coronal images.The assessment is conducted according to
a five-point scale of 0–4, where MTA 0 and MTA 1 are con-
sidered normal. InMTA 0, the width of the choroid fissure and
temporal horn, and the height of the hippocampal formation
are normal; in MTA 1, only the width of the choroid fissure is
slightly increased. MTA2-4 represent increasing degrees of
atrophy. MTA 2 has increased width of the choroid fissure
and temporal horn, and slightly decreased height of the hip-
pocampus. MTA 2 is pathological in patients younger than
70 years of age. MTA 3 has severly increased width of the
choroid fissure and temporal horn, and decreased height of the
hippocampal formation. MTA 3 is pathological in all patients
under 80 years of age. MTA 4 represents severe increase in
width of the choroid fissure and temporal horn, and a severly
decreased hippocampal height. MTA 4 must always be per-
ceived as pathological, regardless of the patient’s age (Fig. 1)
[23].Several studies have investigated the cut-off for normal
and pathological MTA as well as the effect of demographic
variables, such as age, gender and education; average values
of the left and the right side have been proposed [24, 25].
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Fig. 2 A. Rating of medial temporal atrophy (MTA) on MR.
Interpretation key. Answers given as (right/ left). Numbers equal the
corresponding image in the supplementary PDF file. a/6) MTA0/0. b/
16) MTA0 right and MTA0-1 on the left side. c/2) MTA0/1. d/4)
MTA1/0-1. Both are normal. e/5) MTA1/1. f/17) MTA1/1. g/11)
MTA1/1. Note the small cyst in the right hippocampus. h/8)MTA1/1. i/
1) MTA2/2. Artefacts are not disturbing the rating process. The
parahippocampal gyri are not atrophied. The sulci are closed. j/10)
MTA2/2. k/15) MTA2/2. On the right side the image is too far behind
the rating point. Left is optimal here. l/18) MTA2/2m/14) MTA1/3. On
the right side MTA is turning into MTA2 and on the left side MTA just
passed fromMTA2 into MTA3. n/–12)MTA2/2.The left MTA is turning
intoMTA3. o/13)MTA2/2. Here you need to have surrounding images to
be sure of the grading. Right side might turn intoMTA3. p/3)MTA3/2. A
fetal band/septum on the left side. Cut it in your mind and the
hippocampus will be released. q/9) MTA2-3 /2. Here it is difficult to
rate. You need to have several images in a row, but even then it is
difficult. The hippocampi are atrophic but there is no passage of
cerebrospinal fluid around the hippocampi in this image r/7) MTA3/3.
The widening of the ventricles are pronounced and sometimes the
distinction between widening of ventricles and hydrocephalus of other
reasons is difficult. In this case the entorhinal cortex and parahippocampal
gyri are atrophied as well which makes atrophy as a cause more likely. s/
19) MTA4/ 3–4. This image is noisy and it’s difficult to distinguish the
entorhinal cortex from the hippocampi and parahippocampal gyri. t/20)
MTA4/4.The right side is more atrophic than the left side. B. Rating of
MTA on CT. Interpretation key. Answers given as (right/ left). Numbers
equal the corresponding image in the supplementary PDF file. a/19)
MTA0/0. b/10) MTA1/0. c/16) MTA0-1/1. d/7) MTA1/0. Basal
artefacts and an acute infarction in the left temporal lobe. e/14)
MTA1/1. f/18) MTA1/2. g/11) MTA2/2. Maybe too anterior on the
right side for rating. h/12) MTA1/2-3. Difficult to rate on the left side.
Hippocampus is thin. MTA3 is more likely. i/20)MTA2/2. j/3) MTA2/2.
It is too anterior to rate the right side, parts of amygdala are still remaining
and on the left side it is almost too far posteriorly. k/6) MTA1/2.Basal
artefacts make it more difficult to rate. Left side is MTA2 but is turning
towards MTA3. l/1)MTA3/0.Asymmetric MTA. Note the wider Sylvian
fissure on the right side. m/4) MTA2-3.More atrophy on the left side.
Thin hippocampi, wide temporal horns, wide sulci beneath, wide
hippocampal sulci. n/15) MTA2/3. Difficult to be sure on a single
image. o/8) MTA2/3. Right side is between 2 and 3 and left side
between 3 and 4. Note the differences in lateral ventricle size. p/2)
MTA3/3. Difficult to rate on just one image. The hippocampi adheres to
the ventricular wall on both sides. The hippocampi are thin and the fissura
hippocampi are wide. The temporal horns are starting to widen.
Parahippocampal gyri are thin and the sulci beneath it is wide. q/13)
MTA3/3.The hippocampus on the left side has a strange formation -
maybe it is not fully rotated. r/17) MTA3/3.Too anterior on both sides.
Parts of amygdala are remaining bilaterally. Hippocampi are thin but the
sulci beneath are not wide. s/5)MTA4/4. Right side is a bit too anterior for
rating. t/9)MTA4/4
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However average values may not be optimal for use in the
clinical routine and more suited for research purposes.
The MTA scale was originally developed for the assessment
ofMR images, but current high quality CTscans can also be used
(Fig. 2) [26]. The MTA scale has demonstrated significant cor-
relation with manual measurements of the hippocampus, and
increased clinical relevance when seen in association with cog-
nitive function [23]. The sensitivity and specificity are compara-
ble to automated methods for volume measurement and calcula-
tions of volume of cortical thickness [27]. Inter- and intrarater
reliability are very high in experienced raters, but may be slightly
lower for raters if no prior consensus between raters has been
established on cases [28].
Global cortical atrophy – GCA Scale
The global cortical atrophy (GCA) scale was first devel-
oped by Pasquier et al. in 1996 for the purpose of
assessing cerebral atrophy in patients with poststroke de-
mentia [29]. The scale was subsequently further refined
and adapted to enable quicker assessment in dementia
[19]. Visual assessment of cortical atrophy reflects not
only the degree of general cortical atrophy but also the
degree of lobar and regional atrophy, which should be
commented upon in the radiological report [30]. This is
of particluar importance since atypical forms of AD are
recognized with more frontal or posterior atrophy, rather
than the temporal atrophy seen in more typical cases [31].
Widening of sulci may be secondary to atrophy of the
cortex and/or the white matter, why the term cortical at-
rophy in a strict meaning should only be used when the
cortical thickness has been measured. Widening of sulci
and gyral volume loss can be assessed using a 4-point
scale, GCA 0–3 [32]. Normal sulci have GCA grade 0,
slight widening of sulci classifies as GCA 1, gyral volume
loss is categorized as GCA 2 and pronounced widening of
Fig. 2 (continued)
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sulci with severe volume loss, so called Bknife blade at-
rophy^ is labelled GCA 3 (Fig. 3). Cortical atrophy can
also be assessed with substansial agreement between CT
and MRI [26].
Fig. 3 A. Global cortical atrophy (GCA) rating on MR. Interpretation
key. Numbers equal the corresponding image in the supplementary PDF
file. a/1) GCA0. b/17) GCA0-1. c/7) GCA0-1. Note the powerful
widening of the lateral ventricles and especially the frontal horns.
Normal pressure hydrocephalus? d/8) GCA0-1 with bifrontal GCA1.
Note the widening of the posterior horns of the lateral ventricles. e/14)
Bifrontal GCA1 and biparietal GCA0. Note the wide lateral ventricles. f/
11)GCA0. Some atrophy of one or two of the temporal gyri andwidening
of the Sylvian fissure, especially on the left side, GCA2. g/2)GCA1 in the
parietal lobe. GCA1 and 2 in the frontal lobes. h/4) GCA1. GCA2 in the
left side at the junction between the frontal and parietal lobes. i/5)GCA1-
2, but mostly GCA2. j/16) GCA1 going towards GCA2. k/9) GCA1.
Maybe atrophy in the frontal midsagital region with mild atrophy of the
anterior cingulate gyri, GCA2? l/6) GCA2 m/13) BifrontalGCA1 and
biparietal GCA2. n/20) GCA2, more atrophy left parietal. o/18)
Bifrontal GCA2 and biparietal GCA1. p/19) GCA0 except for anterior
gyri in both temporal lobes, GCA 2–3 left temporal and GCA1-2 right
temporal. q/3) GCA2 in the left frontal lobe and GCA2-3 in the right. A
few gyri with GCA3.GCA0-1 in the parietal lobes. Note the widening of
the frontal horns of lateral ventricles and the atrophy of the anterior
cingulate gyri. r/10) BifrontalGCA 2–3 and biparietal GCA0-1. Note
atrophy of the cingulate gyrus and wide frontal horns. s/12) GCA3 in
the temporal lobe on the left side. GCA1 on the right side and GCA2 in
the cerebellum. t/15) GCA2 and maybe GCA3 in the Sylvian fissure.
Biparietal GCA1. B. Global cortical atrophy (GCA) rating on CT.
Interpretation key. Numbers equal the corresponding image in the
supplementary PDF file. a/1) GCA0 b/17) GCA0-1. c/5) GCA1. d/2)
GCA1. e/8) GCA1. f/10) GCA1. g/18) GCA1 in the right hemisphere
and GCA2 in left hemisphere. h/9) GCA1 in the more frontal part of the
frontal lobes. GCA2 in general. i/19) In-between GCA1-2, but closer to
GCA2. j/13) In-between GCA1-2, GCA2 bifrontal. Note the cavum septi
pellucidi. k/3) Bifrontal GCA2 and biparietal GCA1.Note the wide
frontal horns. l/6) Bifrontal GCA2, biparietal GCA1. m/7) GCA2
fronto-parietal. n/20) GCA2. o/16) GCA2, frontal lobe left.GCA1 in the
right frontal lobe and GCA0 in the parietal lobes. Note the atrophy in the
anterior cingulate gyri. p/11)Biparietal GCA2 and bifrontal GCA1. q/14)
Another image of the same patient, GCA2. r/12)Note the side difference.
GCA2 along the left hemisphere, GCA1 on the right side. s/15) GCA2 in
supraorbital part of the frontal lobes and in the anterior part of the
temporal lobes.GCA0 in the more posterior part of the temporal lobes.
t/4) GCA3 in a few parietal gyri on the right side. Bifrontal GCA2 and
GCA1 left parietal
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White matter changes – Fazekas’ scale
The Fazekas’ scale was first constructed in 1987 in order
to standardize the visual assessment of white matter
changes seen on MRI. The scale has been used in a large
number of publications on white matter changes and is
included here because of its simplicity and applicability
on CT and MRI, and we consequently recommend its use
in the clinical dementia assessment. The Fazekas’ scale
includes assessment on axial T2-weighted or T2 FLAIR
images for the whole brain and has four increments. Caps
and bands, a rim of white matter hyperintensity around
the ventricles, are seen as a normal finding in the brain.
Grade 0 has no or occasional punctate white matter
changes and grade 1 has multiple punctate white matter
changes, which can be seen in all ages and is common in
patients older than 65 years of age. The presence of a
small number of such changes usually lack clinical
significance. Grade 2 implies incipient confluence or
bridging of punctate changes and grade 3 consists of con-
fluent white matter changes. Grade 2 is regarded as path-
ological in patients younger than approximately 70 years
of age, while grade 3 is always pathological (Fig. 4). A
modified version of the Fazekas’ scale, the age related
white matter changes (ARWMC) scale [33] includes anal-
ysis in further topographical regions.
Extended imaging assessment
Posterior atrophy – Koedam scale
The Koedam scale was developed 2011, to enable easy
visual rating of posterior atrophy, that is atrophy of the
parietal lobe including the precuneus, which may be a
feature of Alzheimer’s disease [34]. Posterior atrophy
Fig. 3 (continued)
86 Insights Imaging (2017) 8:79–90
has been suggested to be of specific importance in pa-
tients with early Alzheimer’s disease and no or minimal
medial temporal atrophy [34]. Visual assessment is done
in all three planes – axial, sagittal and coronal, with focus
on the parietal cortex, the precuneus and the parieto-
occipital sulcus. The scale has 4 increments with 0 = no
Fig. 4 A. Rating of white matter hyperintensities (WMH) according to
the Fazekas scale on MRI. Interpretation key. Numbers equal the
corresponding image in the supplementary PDF file. a/2) Fazekas 0.
Entire cerebrum is without punctate WMH. WMH in the pons and in
the cerebellum are not included in the rating – but should be mentioned
in the referral. b/19) Fazekas 1. c/14) Fazekas 1. Still punctate WMH. d/
15) Fazekas 1. One single lesion < 2 cm and some punctate lesions. e/1)
Fazekas 1. Small punctate WMH grouped but separated along the left
posterior horn of the lateral ventricle. f/3) Fazekas 1. Grouped but not
linked WMH. g/9) Fazekas 1. Many separate WMH. h/12) Fazekas 1. i/
18) Fazekas 1. All WMH are seen as separate dots. No connecting
bridges. j/17) Fazekas 2, Connecting bridges. k/20) Fazekas 2.
Connecting bridges close to the right posterior horn. l/4) Fazekas 2.
WMH are linked, but can still be seen as separate lesions. m/7) Fazekas
2. The WMH are beginning to confluate. Individual WMH are still seen.
n/13) Fazekas 2. Connecting bridges between lesions. o/10) Fazekas 2.
Borderline to Fazekas 3 with bridging between WMH still visible,
starting to confluate. p/11) Fazekas 2–3. q/8) Fazekas 3. Borderline
Fazekas 2, but the WMH on the left side measures more than 2 cm and
groupedWMH are confluent to some extent. r/5) Fazekas 3. s/6) Fazekas
3. Confluent lesions around the frontal horns and confluent thin lesions in
the right external capsule, and not so pronounced in the same area on the
left side. t/16) Fazekas 3 .B. Rating of white matter hyperintensities
(WMH) according to the Fazekas scale on CT. Interpretation key.
Numbers equal the corresponding image in the supplementary PDF file.
a/2)Fazekas 0–1. No lesions are seen, however punctate lesion may exist.
b/7) Fazekas 1. Punctate lesions frontal bilaterally, more obvious right
frontal. c/11) Fazekas 1. Lesion in the external capsule bilaterally. d/17)
Fazekas 1.Single lesion frontal left. e/15) Fazekas 1. Just small caps
around the frontal horns and 2 smaller diffuse punctate lesions in the
frontal lobe on the right side. f/20) Fazekas 2. Lesions in the external
capsules with connecting bridges. g/3) Fazekas 2. Small lesions close to
frontal and posterior horns and small lesions in the external capsules.h/4)
Fazekas 2. Small lesions in the external capsule, bilaterally. i/13) Fazekas
2. j/18) Fazekas 2. Lesions in the external capsules. k/12)Fazekas 2–3
depending on the size of the lesions surrounding posterior horns. l/
1)Fazekas 3. Confluating lesions around the frontal and posterior horns
and in both external capsules.m/5) Fazekas 3.n/6) Fazekas 3. o/8)Fazekas
3. p/9) Fazekas 3. q/10) Fazekas 3. r/14) Fazekas 3. s/19) Fazekas 3. t/16)
Fazekas 3
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atrophy, 1 = minimal atrophy, 2 = moderate atrophy, 3 =
severe atrophy.
Small vessel disease – The STRIVE criteria
Markers of small vessel disease have become increasingly
important for the evaluation of patients with dementia, and
have been suggested to have a contributory as well as a caus-
ative role in the neurodegenerative disease process. The Bstan-
dards for research into small vessel disease^ were established
in 2013 summarizing the scales and criteria and proposing a
terminology to be used in the realm of small vessel disease
imaging. Important small vessel disease markers are: 1.
Cerebral microbleeds, seen as punctate foci of hypointensity
on susceptibility sensitive sequences. The location of cerebral
microbleeds is also of importance to mention in reports as
deep bleeds represent underlying hypertensive arteriopathy,
and lobar cerebral amyloid angiopathy. 2. Cortical superficial
siderosis implies gyriform linear hypointensities that have
been suggested to be a sensitive markers of cerebral amyloid
angiopathy. 3. Lacunes and recent small subcortical infarcts
are other terms that preferably should be used depending on
imaging manifestations. Although white matter changes are
part of the small vessel disease spectrum, they are discussed
separately above.
Conclusion of the radiological report
Providing that the imaging has been conducted as part of a
dementia investigation, a description of the findings, using the
rating scales above, should be followed by an assessment of
whether the findings are pathological or not taking the age of
the patient into account. In addition, the radiologist should
conclude if the described pattern could be consistent with
the clinically suspected dementia disorder. Atrophy of the me-
dial temporal lobes can support a clinical suspicion of
Alzheimer’s disease, especially if there is a progression
Fig. 4 (continued)
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compared with previous imaging studies. It should, however,
be noted that atrophy of the medial temporal lobes may also be
found in other dementia disorders , e.g. Lewy Body Dementia
and frontotemporal dementia. Vascular dementia can be con-
sidered unlikely if signs of cerebrovascular ischemia, strategi-
cal infarcts or microbleeds are missing. The final impression
will thus provide a summary of the general imaging assess-
ment, and also relate to clinical suspicion, and, if available,
other examinations performed, such as a PET scan (e.g. glu-
cose metabolism) or a SPECT (regional blood flow). This will
improve the accuracy of the diagnosis of dementia disorders in
clinical practice.
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